Eli Lilly to buy gene therapy company Akouos for $487 million

27 Oct 2022

Eli Lilly to acquire Loxo Oncology for $8 bn in cash

09 Jan 2019

Loxo’s oncology drug Vitrakvi, priced at $32,800 per month, and experimental follow-up drug LOXO-195, on which Bayer is also a partner, together could generate annual sales of about $750 million

Eli Lilly to buy privately-held AurKa Pharma in a deal potentially worth $575 mn

14 May 2018

Eli Lilly to buy Armo BioSciences for $1.6 bn

11 May 2018

US pharmaceutical company Eli Lilly and Co yesterday struck a deal to buy Armo BioSciences Inc for about $1.6 billion in order to strengthen its immuno-oncology portfolio

Eli Lilly to buy Boehringer Ingelheim's US pet vaccines business for $885 mn

05 Oct 2016

Eli Lilly’s stock hit after evacetrapib study ended

13 Oct 2015

Eli Lilly wins key cancer drug patent case in UK

26 Jun 2015

Eli Lily to divest US veterinary assets to Virbac

27 Oct 2014

Takeda Pharmaceutical Co, Eli Lilly lose $9 bn damages over Actos drug

30 Aug 2014

Eli Lilly to buy Novartis AG's animal health business for $5.4 bn

22 Apr 2014

Eli Lilly and Co today struck a deal to buy Swiss drugmaker Novartis AG's animal health business for $5.4 billion in cash in order to strengthen and diversify its own animal health business, Elanco.

Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.

Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!

Start your free subscription today!

Latest articles on Eli Lilly from Informachine

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

09 Jul 2025

FDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients

FDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients

26 Jun 2025

Lilly declares third-quarter 2025 dividend

Lilly declares third-quarter 2025 dividend

25 Jun 2025

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

25 Jun 2025

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

25 Jun 2025

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

04 Jun 2025

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

04 Jun 2025

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

02 Jun 2025

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

02 Jun 2025

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

12 May 2025

View details about the software product Informachine News Trackers